See more : Gerdau S.A. (GGBR4.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Orphazyme A/S (OZYMF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orphazyme A/S, a leading company in the Biotechnology industry within the Healthcare sector.
- Cineworld Group plc (CNNWQ) Income Statement Analysis – Financial Results
- Dacian Gold Limited (DCCNF) Income Statement Analysis – Financial Results
- Flower One Holdings Inc. (FONE.CN) Income Statement Analysis – Financial Results
- Great Tang Bid Technology, Inc. (ESPI) Income Statement Analysis – Financial Results
- Khandelwal Extractions Limited (ZKHANDEN.BO) Income Statement Analysis – Financial Results
Orphazyme A/S (OZYMF)
About Orphazyme A/S
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cell protective properties of the heat shock response, which protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. Its lead candidate is the Arimoclomol, which is in clinical development for diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 36.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 782.00K | 18.11M | 5.20M | 3.80M | 1.37M | 746.00K | 572.00K | 0.00 |
| Gross Profit | 0.00 | -782.00K | 18.08M | -5.20M | -3.80M | -1.37M | -746.00K | -572.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 49.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 229.94M | 261.14M | 285.41M | 154.95M | 99.05M | 55.82M | 45.87M |
| General & Administrative | 12.88K | 41.24K | 421.44M | 342.20M | 49.84M | 75.33M | 31.99M | 7.70M | 7.22M |
| Selling & Marketing | 0.00 | 39.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.88K | 40.46M | 421.44M | 342.20M | 49.84M | 75.33M | 31.99M | 7.70M | 7.22M |
| Other Expenses | 14.16K | 0.00 | 18.11M | 5.20M | 699.00K | 1.37M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 27.04K | 40.46M | 669.50M | 608.53M | 335.95M | 231.65M | 131.04M | 63.52M | 53.09M |
| Cost & Expenses | 27.04K | 41.24M | 669.50M | 608.53M | 335.95M | 231.65M | 131.04M | 63.52M | 53.09M |
| Interest Income | 786.00K | 193.00K | 37.00K | 45.00K | 316.00K | 5.00K | 0.00 | 2.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 9.46M | 14.11M | 4.80M | 3.45M | 647.00K | 71.00K | 40.00 |
| Depreciation & Amortization | 782.00 | 782.00K | 18.11M | 5.20M | 3.80M | 1.37M | 746.00K | 572.00K | 554.00K |
| EBITDA | -12.10K | -40.46M | -603.91M | -615.70M | -334.31M | -230.28M | -130.27M | -62.95M | -58.47M |
| EBITDA Ratio | 0.00% | 0.00% | -1,700.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -27.04K | -41.24M | -633.30M | -608.53M | -335.95M | -231.65M | -131.04M | -63.52M | -53.09M |
| Operating Income Ratio | 0.00% | 0.00% | -1,749.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 993.00 | 185.00K | 549.87M | -26.63M | -7.04M | -3.45M | -662.00K | 85.00K | -5.88M |
| Income Before Tax | -26.05K | -41.06M | -631.48M | -635.16M | -343.00M | -235.10M | -131.70M | -63.44M | -53.40M |
| Income Before Tax Ratio | 0.00% | 0.00% | -1,744.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.75M | -4.94M | -1.92M | -5.50M | -5.50M | -5.50M | -5.50M | -5.69M |
| Net Income | -26.05M | -110.59M | -626.54M | -633.25M | -337.50M | -229.60M | -126.20M | -57.94M | -47.71M |
| Net Income Ratio | 0.00% | 0.00% | -1,731.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -3.14 | -17.94 | -22.32 | -16.87 | -11.47 | -10.43 | -5.89 | -4.66 |
| EPS Diluted | 0.00 | -3.14 | -17.94 | -22.32 | -16.87 | -11.47 | -10.43 | -5.65 | -4.66 |
| Weighted Avg Shares Out | 35.00M | 35.27M | 34.92M | 28.37M | 20.00M | 20.01M | 12.10M | 9.83M | 10.25M |
| Weighted Avg Shares Out (Dil) | 35.31M | 35.27M | 34.92M | 28.37M | 20.00M | 20.01M | 12.10M | 10.25M | 10.25M |
Orphazyme completes sale of substantially all of its assets and business activities to KemPharm
Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.
Why Entera Bio, Orphazyme, Bellerophon Are Moving Today
Kim Stratton, CEO, resigns from Orphazyme
CytRx Highlights Orphazyme's Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C
Orphazyme closes its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe
Orphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C
Source: https://incomestatements.info
Category: Stock Reports